Clinical Trials Logo

Solid Tumors clinical trials

View clinical trials related to Solid Tumors.

Filter by:

NCT ID: NCT02909452 Completed - Neoplasms Clinical Trials

Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Start date: September 20, 2016
Phase: Phase 1
Study type: Interventional

The objectives of this study are to explore different dosing levels and schedules of entinostat in combination with pembrolizumab in patients with advanced solid tumors, in terms of safety, tolerability, pharmacokinetics (PK), impact on immune correlatives, and efficacy

NCT ID: NCT02903914 Completed - Lung Cancer Clinical Trials

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

Start date: September 14, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

This study is an open-label Phase 1/Phase 2 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors.

NCT ID: NCT02897778 Completed - Neoplasms Clinical Trials

Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors

Start date: August 24, 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the effect of entinostat on heart rate and other electrocardiogram (ECG) parameters. This study will also evaluate the safety and tolerability of entinostat, as well as pharmacokinetic and pharmacodynamic parameters.

NCT ID: NCT02881190 Completed - Solid Tumors Clinical Trials

Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid Tumors

Start date: December 14, 2015
Phase: Phase 1
Study type: Interventional

A tolerance, safety and pharmacokinetic ascending dose phase I Study of RC48-ADC administered intravenously to subjects with HER2-positive malignant in advanced malignant solid tumors.

NCT ID: NCT02881138 Completed - Solid Tumors Clinical Trials

A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors

Start date: March 1, 2016
Phase: Phase 1
Study type: Interventional

A Phase I Study to Evaluate the Safety,Tolerability and Pharmacokinetics of RC48-ADC for Injection in Subjects With Advanced Malignant Solid Tumors With HER2-positive

NCT ID: NCT02857166 Completed - Solid Tumors Clinical Trials

Study of JS001 in Participants With Advanced Solid Tumors

Start date: March 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerance and Dose-Limiting Toxicity (DLT) of Recombinant humanized anti-PD-1 monoclonal antibody (JS001) in patients with advanced solid tumors.

NCT ID: NCT02834611 Completed - Cancer Clinical Trials

Ceramide NanoLiposome in Patients With Advanced Solid Tumors

Start date: March 15, 2017
Phase: Phase 1
Study type: Interventional

This study is a dose escalation study of Ceramide NanoLiposome in patients with advanced solid tumors.

NCT ID: NCT02828930 Completed - Solid Tumors Clinical Trials

A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)

Start date: September 8, 2016
Phase: Phase 1
Study type: Interventional

The purpose of this single-center, open-label, non-randomized study is to assess the excretion balance, pharmacokinetics, metabolism and absolute oral bioavailability of [14C]-labeled idasanutlin administered orally and [13C]-labeled idasanutlin administered intravenously in a single cohort of eligible participants. Participants will be screened for participation in this study within 21 days of receiving the first dose of study drug on Day 1. Treatment period will continue up to Day 28 after which participants will enter 28 day follow-up or the optional treatment extension of idasanutlin, depending on safety parameters and as per opinion of the Investigator.

NCT ID: NCT02827968 Completed - Solid Tumors Clinical Trials

Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors

Start date: January 13, 2017
Phase: Phase 1
Study type: Interventional

This is an open label, dose escalation study to evaluate the safety and tolerability of KN035 in advanced and metastatic solid tumor.

NCT ID: NCT02762981 Completed - Solid Tumors Clinical Trials

Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors

Start date: May 23, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study was to assess the safety of the combination of relacorilant (CORT125134), a novel glucocorticoid receptor (GR) antagonist, and nab- paclitaxel in participants with solid tumors and to determine the preliminary efficacy of the combination of relacorilant and nab-paclitaxel. The structure for the study was a single arm, non-randomized, open- label, multicenter trial with no control group.